Search results
Results from the WOW.Com Content Network
On Tuesday, Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 ...
Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.
For premium support please call: 800-290-4726 more ways to reach us
CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, November 12, 2024, to review the company’s third quarter 2024 financial results and provide business updates.
CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced key expected 2025 milestones across its clinical programs, growing pipeline, and leading RNA medicines platform ...
Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X (formerly Twitter) and LinkedIn. Investor Contact: Kate Rausch +1 617-949-4827 krausch@wavelifesci.com. Media Contact: Alicia Suter +1 617-949-4817 asuter@wavelifesci.com. 11/26/2024 ...
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Wave Life Sciences wasn’t one of them. The 10 stocks that made ...
For premium support please call: 800-290-4726 more ways to reach us